ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMM Immupharma Plc

2.20
0.06 (2.80%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.06 2.80% 2.20 2.10 2.18 2.20 2.19 2.19 604,698 16:29:55
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.81M -0.0114 -1.93 7.33M

Immupharma PLC Technology review published-Nature Communications

26/02/2019 7:02am

RNS Non-Regulatory


TIDMIMM

Immupharma PLC

26 February 2019

RNS REACH 26 February 2019

ImmuPharma PLC

("ImmuPharma" or the "Company")

Technology review published in Nature Communications

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce that on 25 February 2019, the peer reviewed research journal 'Nature Communications' published a fundamental scientific publication on the proprietary technology Urelix(TM) from UREkA Sarl ("Ureka"), ImmuPharma's subsidiary.

Ureka, based at the IECB in Bordeaux, France, is carrying out research into novel peptide molecules to generate drug candidates for many diseases. The publication describes for the first time the unique properties of oligourea foldamers as a tool to improve the pharmaceutical properties of peptides. Further improvements not yet described here are related to more focused medical indications. One of the first focus areas has been GLP-1 analogues for the treatment of Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis) as proof of concept for Ureka's technology.

Further applications of the Urelix(TM) technology include protein/protein interactions, notably in cancer, and improvement of marketed efficacious peptides allowing additional long lasting patent protection, paving the way for a life cycle management franchise. Novel patented technologies are also currently implemented to cover other aspects of the improvement of peptides including potential oral delivery.

The publication was entitled: "Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo" and was authored by a number of researchers working within Ureka including Dr Robert Zimmer, ImmuPharma's Chief Scientific Officer and Dr Sébastien R. Goudreau, Head of Research at Ureka.

Introduction to the Publication

Peptides have gained so much attention in the last decade that they are now part of the main strategies, with small molecules and biologics, for developing new medicines. Despite substantial progress, the successful development of peptides as drugs still requires a number of limitations to be addressed, including short in vivo half-lives and poor membrane permeability.

Commenting, Dr Robert Zimmer, ImmuPharma's Chief Scientific Officer, said: "I am very proud of the achievement of the research team in Ureka since it started in 2014, having built a team of skilled people and expanded our collaboration with the CNRS, developing an exciting technology backed by a strong patent portfolio. As such, a pleasing validation of years of research by our scientific team and collaborators, giving us further confidence in the long term potential of our Ureka platform."

Commenting, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, said: "Natural peptides play key roles in human biological processes and are effective and selective signaling molecules that bind to specific receptors on cells. Using natural peptides as drugs is not so effective because they are quickly broken down. To put it simply, our technology overcomes these challenges and represents an intelligent way to design novel drugs. The global peptide therapeutics market achieved sales of $30 billion in 2018."

The full paper can now be downloaded from: http://dx.doi.org/10.1038/s41467-019-08793-y or accessed via Nature Communications website: https://www.nature.com/search?q=immupharma.

 
 
  For further information please contact: 
   ImmuPharma plc (www.immupharma.com)           + 44 (0) 207 152 4080 
   Dimitri Dimitriou, Chief Executive Officer 
   Lisa Baderoon, Head of Investor Relations     + 44 (0) 7721 413496 
 
    SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin                                 +44 (0) 203 368 8974 
    Vassil Kirtchev 
 
    Stanford Capital Partners (Joint Broker) 
    Patrick Claridge, John Howes                 +44 (0) 203 815 8880 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                 +44 (0) 1483 413500 
  About Nature Communications 
  Nature Communications is an open access journal that publishes 
  high-quality research from all areas of the natural sciences. 
  Papers published by the journal represent important advances 
  of significance to specialists within each field. For more 
  information go to: https://www.nature.com 
  About the IECB 
  The Institut Européen de Chimie et Biologie (European 
  Institute of Chemistry and Biology) is an international and 
  interdisciplinary research team incubator, placed under the 
  joint authority of the CNRS, Inserm and the University of 
  Bordeaux. The CNRS is a public organization under the responsibility 
  of the French Ministry of Education and Research. The CNRS 
  is top of the Nature Index (The Nature Index ranks publication 
  productivity and is one indicator of global high-quality 
  research output ) and has over 31,000 staff and EUR3.2 bn 
  annual budget. 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRASEAFWIFUSEFE

(END) Dow Jones Newswires

February 26, 2019 02:02 ET (07:02 GMT)

1 Year Immupharma Chart

1 Year Immupharma Chart

1 Month Immupharma Chart

1 Month Immupharma Chart

Your Recent History

Delayed Upgrade Clock